ImaginAb

ImaginAb is a clinical stage, revenue-generating global biotechnology company founded in 2007. It is focused on developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology. The company operates in the Biotechnology and Health Care industries from its headquarters in the United States.

ImaginAb's latest funding round was a $12.80M Venture Round investment on 03 June 2021. The investors in this round included Adage Capital Management, Norginer Ventures, Cycad Group, Theravance Biopharma, and James Pallotta. The company's slogan emphasizes its commitment to being the leading diagnostic and treatment choice, ultimately aiming to improve patients' lives by providing advanced imaging and therapy solutions.